Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C30H33ClN4O2.CH4O3S |
| Molecular Weight | 613.167 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(O)(=O)=O.CC(C)[C@@H](N(CCCN)C(=O)C1=CC=C(C)C=C1)C2=NC3=C(C=CC(Cl)=C3)C(=O)N2CC4=CC=CC=C4
InChI
InChIKey=MRKSDPIHUJSKRA-HZPIKELBSA-N
InChI=1S/C30H33ClN4O2.CH4O3S/c1-20(2)27(34(17-7-16-32)29(36)23-12-10-21(3)11-13-23)28-33-26-18-24(31)14-15-25(26)30(37)35(28)19-22-8-5-4-6-9-22;1-5(2,3)4/h4-6,8-15,18,20,27H,7,16-17,19,32H2,1-3H3;1H3,(H,2,3,4)/t27-;/m1./s1
| Molecular Formula | CH4O3S |
| Molecular Weight | 96.106 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C30H33ClN4O2 |
| Molecular Weight | 517.062 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Ispinesib (SB-715992) is a potent, specific and reversible inhibitor of kinesin spindle protein (KSP). KSP, also known as HsEg5, is a kinesin that plays an essential role in the formation of a bipolar mitotic spindle and is required for cell cycle progression through mitosis. Ispinesib is the highly specific small-molecule inhibitor of KSP tested for the treatment of human disease. It causes mitotic arrest and growth inhibition in several human tumor cell lines and is currently being tested in multiple phase II clinical trials for treatment of the breast cancer and renal cell cancer.
Originator
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
281 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/20712019 |
9 mg/m² single, intravenous dose: 9 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
ISPINESIB plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3811 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/20712019 |
9 mg/m² single, intravenous dose: 9 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
ISPINESIB plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
|
349 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/22123335 |
10 mg/m² single, intravenous dose: 10 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
ISPINESIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
33 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/20712019 |
9 mg/m² single, intravenous dose: 9 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
ISPINESIB plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
9.5% EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/20712019 |
9 mg/m² single, intravenous dose: 9 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
ISPINESIB plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Discovery of (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a kinesin spindle protein inhibitor and potential anticancer agent. | 2011-10-13 |
|
| A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children's Oncology Group phase I consortium study. | 2010-12-15 |
|
| Novel benzimidazole inhibitors bind to a unique site in the kinesin spindle protein motor domain. | 2010-09-28 |
|
| Functional characterisation and drug target validation of a mitotic kinesin-13 in Trypanosoma brucei. | 2010-08-19 |
|
| Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer. | 2010-01-15 |
|
| Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. | 2009-12-15 |
|
| Thermodynamics of nucleotide and inhibitor binding to wild-type and ispinesib-resistant forms of human kinesin spindle protein. | 2009-11-24 |
|
| KIF11 inhibition for glioblastoma treatment: reason to hope or a struggle with the brain? | 2009-06-22 |
|
| A Bayesian population PK-PD model for ispinesib/docetaxel combination-induced myelosuppression. | 2009-02 |
|
| Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes. | 2008-09 |
|
| Progress on kinesin spindle protein inhibitors as anti-cancer agents. | 2008-08 |
|
| Conformation-dependent ligand regulation of ATP hydrolysis by human KSP: activation of basal hydrolysis and inhibition of microtubule-stimulated hydrolysis by a single, small molecule modulator. | 2008-06-18 |
|
| A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). | 2008-06 |
|
| Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. | 2008-06 |
|
| A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. | 2008-06 |
|
| Mechanism of inhibition of human KSP by ispinesib. | 2008-03-18 |
|
| A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours. | 2008-03-11 |
|
| A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer. | 2008-03 |
|
| Promising novel cytotoxic agents and combinations in metastatic prostate cancer. | 2008-02-28 |
|
| ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism. | 2007-11 |
|
| American Chemical Society--233rd National Meeting. Kinesin spindle protein inhibitors. 25-29 March 2007, Chicago, IL, USA. | 2007-05 |
|
| A Bayesian population PK-PD model of ispinesib-induced myelosuppression. | 2007-01 |
|
| Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line. | 2006-01-24 |
|
| Highlights from the International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, And Clinical Applications, Philadelphia, PA, November 2005; ECCO 13--The European Cancer Conference, Paris, France, October 30-November 3, 2005. | 2005-12 |
Patents
Sample Use Guides
Patients receive ispinesib (SB-715992) IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Route of Administration:
Intravenous
In vitro, ispinesib at concentrations of 3.3 × 10−5 to 8.5 × 10−11 mol/L inhibited proliferation of all 53 breast cell lines tested. GI50 values spanned a 100-fold range and fall between 10 and 100 nmol/L for most cell lines. (The GI50 value is the drug concentration that results in 50% growth inhibition after 72 h of drug exposure relative to control). Ispinesib exhibited no apparent specificity for histopathologic subtype (luminal A, luminal B, basal) or receptor status (HER2, ER/PR).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:11:46 GMT 2025
by
admin
on
Mon Mar 31 18:11:46 GMT 2025
|
| Record UNII |
R6ZMD4UH3D
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C67440
Created by
admin on Mon Mar 31 18:11:46 GMT 2025 , Edited by admin on Mon Mar 31 18:11:46 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6450816
Created by
admin on Mon Mar 31 18:11:46 GMT 2025 , Edited by admin on Mon Mar 31 18:11:46 GMT 2025
|
PRIMARY | |||
|
R6ZMD4UH3D
Created by
admin on Mon Mar 31 18:11:46 GMT 2025 , Edited by admin on Mon Mar 31 18:11:46 GMT 2025
|
PRIMARY | |||
|
300000042482
Created by
admin on Mon Mar 31 18:11:46 GMT 2025 , Edited by admin on Mon Mar 31 18:11:46 GMT 2025
|
PRIMARY | |||
|
514820-03-2
Created by
admin on Mon Mar 31 18:11:46 GMT 2025 , Edited by admin on Mon Mar 31 18:11:46 GMT 2025
|
PRIMARY | |||
|
CHEMBL2111096
Created by
admin on Mon Mar 31 18:11:46 GMT 2025 , Edited by admin on Mon Mar 31 18:11:46 GMT 2025
|
PRIMARY | |||
|
C77518
Created by
admin on Mon Mar 31 18:11:46 GMT 2025 , Edited by admin on Mon Mar 31 18:11:46 GMT 2025
|
PRIMARY | |||
|
DTXSID70199455
Created by
admin on Mon Mar 31 18:11:46 GMT 2025 , Edited by admin on Mon Mar 31 18:11:46 GMT 2025
|
PRIMARY | |||
|
QQ-11
Created by
admin on Mon Mar 31 18:11:46 GMT 2025 , Edited by admin on Mon Mar 31 18:11:46 GMT 2025
|
PRIMARY | |||
|
DBSALT001998
Created by
admin on Mon Mar 31 18:11:46 GMT 2025 , Edited by admin on Mon Mar 31 18:11:46 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |